Extracorporeal membrane oxygenation (ECMO) has become a more or less accepted standard in the algorithm of advanced acute respiratory distress syndrome therapy in adult patients when all other treatment options have failed. This article reviews the current status of ECMO therapy with particular focus on new technical developments and their potential implications for performance and indications for ECMO therapy.
Introduction
The story of extracorporeal membrane oxygenation (ECMO) in the clinical setting started more than 30 years ago, when Hill et al. [1] reported for the first time the successful use of extracorporeal circulation to treat acute hypoxemic respiratory failure in an adult patient. In 1976, Bartlett [2] was the first to demonstrate the successful use of ECMO in a neonate. Over the years, the use of ECMO therapy underwent substantial changes in indications, techniques and materials used, and its role in the treatment algorithm of acute respiratory distress syndrome (ARDS). The use of ECMO has been a matter of debate from the very beginning, least in adult patients. More than many other unproven but potentially lifesaving therapies, it has the potential to divide clinicians worldwide into friends and foes. There is no doubt that knowledge about the cause, the pathophysiology, and the iatrogenic consequences of treatment strategies used in ARDS patients have markedly increased over the years, and that this knowledge has had an influence on the incidence, the mortality, and, very probably, the need for advanced therapies. However, keeping the potential iatrogenic harm of mechanical ventilation in mind and knowing that substantial progress has been made in pump, oxygenator, and artificial surface development, substantially reducing the potential complications and side effects of extracorporeal circulation, the possibility of using an extrapulmonary, ie, extracorporeal device to support gas exchange and to protect the injured lung further might be more real than it has ever been before.
Short history of extracorporeal membrane oxygenation
Many steps necessary to allow the extracorporeal bypass of heart and lungs had been taken before Clowes and Balser developed the first prototype of a membrane oxygenator suitable for bypass therapy during cardiosurgical procedures in 1956 [3] . These types of oxgenators were a fundamental step in allowing extended extracorporeal perfusion procedures. It was the visionary Bob Bartlett JOBNAME: cocc 11#1 2005 PAGE: 1 OUTPUT: Wed January 5 15:07:37 2005 lww/cocc/91165/COCC11113 Prod.#: COCC11113 who first showed in 1969 in an experimental setting that prolonged extracorporeal bypass therapy was a therapeutic option to treat severe respiratory failure. Of note, this happened only 2 years after the first description of ARDS by Asbaugh et al. In 1972, Hill et al. finally reported the first successful treatment of a 22-year-old ARDS patient using a Bramson lung for a period of 72 hours. In 1976, Bartlett et al. successfully treated the first newborn. In 1979, another pioneer in the field, Luciano Gattinoni, working in Kolobow's laboratories, developed the concept of venovenous extracorporeal lung support based on the principle of the dissociation between oxygenation and carbon dioxide elimination [4] . In 1981, Kolobow and his group, based on experimental and on clinical data, took the important step of analyzing the ECMO experience of the NIH trial [5, 6] . Consequently, Gattinoni et al. [7] were the first to show the successful clinical use of this technique in a larger population of ARDS patients. So far, two randomized controlled trials in adult patients have been performed that were not able to show a benefit of ECMO therapy in the treatment algorithm of ARDS [8, 9] . However, for many reasons that cannot be discussed here, these two studies are far from giving any serious evidence that the appropriate use of ECMO is without benefit in adult severe respiratory failure. In contrast, the UK collaborative neonatal ECMO trial clearly showed the benefits of its use, especially in the most severe cases [10] . There is an ongoing randomized controlled adult ECMO trial in the UK named CESAR; however, the enrollment is obviously much slower than expected. Nevertheless, the study will ideally be completed and analyzed (planned total sample size, 240 patients; start of recruitment, July 23, 2001; enrollment status as of October 8, 2004 , 108 patients; see http://www.cesar-trial.org). So far, we deal with a technique that has been successfully used by experienced teams in neonates and pediatric and adult patients with a consistent low (and decreasing) rate of complications to treat severe hypoxemic respiratory failure [11 • ]. In the treatment algorithm of ARDS, veno-venous ECMO is today mostly accepted as a high-end intervention in patients in whom all other treatment options have failed to improve oxygenation to assure at least basal oxygen supply in a state of life-threatening hypoxemia. In the face of a lack of randomized controlled trial evidence for ECMO therapy in adult patients, this rationale, together with the increasing knowledge of the cause, the pathophysiology, and the iatrogenic consequences of treatment strategies used in ARDS, has led to a marked reduction in its use. Patients treated today have, on average, a much higher lung injury score than some years ago [12, 13] .
Technique and vascular access
Basically, an ECMO unit consists of the vascular access (cannulas), tubing, a driving force (pump), and a gas exchange unit (oxygenator).
In contrast with the NIH trial, the accepted approach for ECMO today is a veno-venous setting in which drainage and the return of blood are realized using heparin-coated spiral-armed percutaneous cannulas in sizes between 21 and 28 French. The bloodstream might be directed in a jugular-femoral, femoro-jugular, or femoro-femoral direction depending on the patient's individual anatomy and the size and length of the cannulas used. In general, the draining cannula (or cannulas if one does not deliver a sufficient flow) should allow a flow as high as 6 L/min without causing too-high negative pressures, thus avoiding additional damage to blood cells. Ideally, one single percutaneous cannulation would allow performance of veno-venous ECMO in adult patients using a double lumen cannula. Double lumen cannulas have been used successfully in neonatal ECMO since the late 1980s [14] . Besides the fact that only one cannulation of a large vessel would potentially be sufficient, a well-designed double lumen cannula would have a defined and well-known recirculation rate for any given flow, whereas recirculation is very much dependent on the cannulas' positions if the usual two-vascular access is used. Even though cannula development in general has made much progress, especially with regard to the relation between inner and outer diameter, such a cannula has not yet been developed. The limited use of such a device might be the reason why companies, at least until now, have not pressed the development of double lumen cannulas for adult patients.
Mostly roller or centrifugal pumps are used to deliver the driving force in an ECMO circuit. The literature is inconsistent with regard to biocompatibility and complication rates comparing these two pump principles, with a slight tendency in favor of the roller pump. According to neonatal US surveillance in 2002, more than 90% of the ECMO procedures are performed while using a roller pump [15] . Nevertheless, the two principles can so far be looked at as being more or less equivalent, even for long-term extracorporeal support. Some centers use two pumps in parallel, thus backing up their unit in case of pump or oxygenator malfunction ( Fig. 1 ). This approach might be reasonable, especially in centers where the incidence of ECMO is too low to have a primed unit available to hook up at all times.
Heparin-coated silicone membrane oxygenators and hollow fiber oxygenators are in use for ECMO. Because of their smaller priming volumes, their higher gas transfer rates and their lower-resistance hollow fiber are at least theoretically superior to silicone membrane oxygenators [16] . However, in the past serious, plasma leakage problems in hollow fiber oxygenators have led either to the use of silicone membrane oxygenators or, at least in some patients, to seriously impaired oxygenator gas exchange and numerous oxygenator changes, thus additionally compromising the patient. For a few years, at least in Europe and Australia, the heparin-coated hollow fiber Jostra Quadrox oxygenator has offered plasma resistance and standing times similar to those of a silicone membrane oxygenator and has been successfully used for ECMO therapy [17] .
New technical developments
Over the years, many attempts have been made to develop new, more biocompatible, and easier to handle pumps. These developments have been directed to pump principles, pump control, and size.
Besides the classic roller and centrifugal pumps, nonocclusive pumps, which have been used in France for neonates and smaller children for years, have been built suitable for use in adult patients [18, 19] . The M-pump has finally been clinically successfully used in adult patients [20] . A nonocclusive pump avoids more or less any stress to corpuscular blood components while abolishing negative pressures acting on the drained blood. However, in consequence, various amounts of blood might be pumped at a time, depending on the pump rate and the intravascular volume status of the patient. Another approach to avoid at least excessive negative pressures is the use of a the servo-control mechanism for the kind of pump used. During servo-controlled pumping, a maximally accepted negative pressure is set. When this pressure limit is reached, the pump automatically reduces its rate down to the rate required to stay within the pressure limit. Simultaneously, an alarm indicates that the flow that has been set is no longer delivered to the patient. Servo-control can be realized in most of the commercially available pump systems.
The most exciting development comes from the miniaturization of high-end pumps able to pump blood flows between 0 and 10 L/min. These pumps have very small priming volumes and can-as so-called intubing pumps-theoretically be integrated at any location of an extracorporeal circulation system. They are controlled by small external units that can be easily placed at the bedside. Inline pumps can support arteriovenous circuits at any time, drive veno-venous or veno-arterial circuits, and offer maximal flexibility in potential applications for extracorporeal lung support procedures. The DeltaSTREAM pump is such a system that has been studied in numerous animal studies and clinically tested for heart surgery and extended cardiac assist purposes in a series of cases [21, 22] (Fig. 2) . So far, the results demonstrate safety and high efficacy at a low rate of damage to blood components. This and similar systems have the potential to generate a breakthrough for extracorporeal circulation in general and for extracorporeal lung support in particular.
Oxygenator development has been directed to the construction of smaller devices with low priming volumes, high gas transfer rates, and a lower resistance against the streaming blood [16] . There are different types of such small, leakage-resistant hollow fiber devices available (for example, Affinity, Medtronic, interventional lung assist, Novalung). These gas exchanging devices have markedly improved streaming characteristics, leading to a very low resistance against the blood flow, thus causing only a small pressure drop over the device. These devices are in different states of approval with regard to countries and the allowed extent of their use. Another very interesting development is the introduction of small silicone rubber hollow fiber oxygenators, reaching gas transfer rates very similar to those of conventional hollow fiber oxygenators [23] .
Bioactive coating of artificial surfaces (cannulas, tubing, and oxygenators) to decrease or even avoid the need for systemic anticoagulation is another important issue that has influenced the rate of complications during ECMO procedures [24, 25] . The use of heparin-coated units allowing acceptance of activated clotting times (ACTs) below 160 seconds has become more or less standard in most European countries, whereas in the US, preferentially, noncoated units are used. In a small series of own ECMO cases, using totally Bioline-coated units, the same amount of nonfractioned heparin usually given for deep vein thrombosis prophylaxis was applied as a continuous intravenous infusion, leading to ACTs between 125 and 140 seconds. No thromboembolic complications were observed. Similar oxygenator standing times were achieved compared with those in ECMO runs with the usual ACT between 140 and 160 seconds. Little is known about the use of heparin-coated ECMO units in patients with heparin/platelet factor 4 (HPF 4) antibodies, very probably responsible for the development of heparin-induced thrombocytopenia type II (HIT II). There are some hints that heparin immobilized on artificial surfaces neither induces HPF 4 antibody formation nor supports its persistence [26] . However, simultaneously, case reports have been published evidencing a very probable relation between HIT II development and thromboembolic complications in patients with heparin-coated cardiac stents [27] . A practical approach might be to use noncoated units in patients in whom the existence of HPF 4 antibodies is known before the ECMO treatment is started and to apply alternative anticoagulants from the very beginning [28] [29] [30] . In patients developing a HIT II during an ECMO run, it might be justified to replace the continuous heparin infusion with an alternative anticoagulant and to continue with the heparin-coated circuit while rigorously monitoring HPF 4 antibodies and thrombocyte count. If there is evidence that HPF 4 antibodies increase or that thrombocyte count further decreases, the unit should be removed and replaced by a noncoated unit as well. In general, heparin as a substance acting late in the coagulation cascade seems not to be the ideal drug to be used for the purpose of biocompatibility. The low prize and its high negative polarity allowing it to be easily attached to artificial surfaces are probably the reasons why heparin is the only bioactive coating commercially available for extracorporeal circulation units. Other attempts have been made to achieve higher biocompatibility and to reduce the activation of the coagulation cascade using different substances with anticoagulative properties, including nitric oxide [31] . The latter is a fascinating approach because it imitates the anticoagulative properties of the natural endothelium cell layer. However, until now, even knowing that effective coating with nitric oxide is possible, researchers do not know enough about its effectiveness over time and the potential costs of commercially available nitric oxide-coated ECMO kits to look at it as more than a future potential option with an exciting physiologic rationale.
Indications and limitations
Extracorporeal membrane oxygenation has undergone substantial changes in its indications over time. The original concept of maintaining normal blood gas values in patients with severe respiratory failure while using arteriovenous extracorporeal lung support and more or less unchanged (and, as we know today, harmful) respiratory patterns failed. The concept of dissociating oxygenation and carbon dioxide removal and to achieve oxygenation via the native lungs and carbon dioxide removal while using veno-venous extracorporeal bypass therapy turned firstly back the view to the question ''What are we doing with the lungs?'' and opened the way for a more gentle treatment of the lungs. The concept of permissive hypercapnia finally markedly diminished extracorporeal carbon dioxide removal as an indication for extracorporeal lung support. ECMO therapy became a high-end therapy for respiratory failure for patients in whom all other treatment options had failed to ensure sufficient tissue oxygenation, mostly defined as a PaO 2 /FiO 2 ratio below 50 mm Hg. Meanwhile, the technique is successfully used even in cases in which lung failure has developed after lung transplantation [32] . However, this development also has its influence on outcome. In a recently published review on the single-center experience in 255 adult ECMO patients, among others, the initial PaO 2 /FiO 2 ratio was identified as a significant predictor of survival [33 • ]. ECMO therapy is still an expensive, staff-consuming, and equipment-consuming procedure; however, for neonates, cost-effectiveness has been clearly shown, and it can be assumed that based on a comparable trial in adult patients, similar results could be expected [34 • ]. Recent years have seen impressive progress in pump technology, oxygenator development, and the ability to coat artificial surfaces with different anticoagulatives to improve biocompatibility. It seems likely that at least some of these promising developments will make their way into the clinical setting, with easier-to-handle ECMO units allowing even lower rates of side effects. Simultaneously, the complication rates in experienced centers using ECMO therapy are consistently low and decreasing. This development will raise the question whether ECMO therapy as a way to ensure sufficient oxygenation and to support consequent lung protective ventilation should be re-evaluated for its potential role in the treatment algorithm of ARDS.
Recent developments and future potentials
In 1983, Ohtake et al. [35] described a simple method to remove carbon dioxide while using the arterial blood pressure in an arteriovenous setting including a hollow fiber oxygenator and called it ''pumpless arteriovenous ECMO.'' Such a device consists simply of two cannulas, short tubing, and an oxygenator (Fig. 3 ). An ultrasound flow meter might indicate the amount of blood passing per minute in the device. The blood flow is determined by the driving force given by the cardiac output and, most important, mean arterial pressure and the resistors of the system, namely, the cannulas and the gas exchange device, with the latter most important [36, 37] . An oxygenator suitable for spontaneous arteriovenous carbon dioxide removal should ideally have an optimized gas transfer rate at a very low resistance against the blood flow. However, to remove reasonable amounts of carbon dioxide, a much lower blood flow is required than to achieve oxygenation. In consequence, arterial cannulas with a maximum size of 15 French are sufficient to eliminate easily 200 mL carbon dioxide per minute and more at blood flow rates higher than 1.5 L/min, assuming that a mean arterial pressure is higher than 70 mm Hg. Knowing that arterialized blood is entering the unit, the amount of oxygen that can be transferred is dependent on the saturation of the incoming arterial blood. With the exception of states of severe hypoxemia leading to an extreme desaturated arterial blood, the amount of oxygen that can be transferred is low. Therefore, it seems appropriate to name this procedure arteriovenous extracorporeal carbon dioxide removal. Several observational studies and some case reports have been published using extracorporeal carbon dioxide removal in patients, describing safety and efficacy and a marked reduction of carbon dioxide partial pressure combined with a pH increase at significantly reduced ventilator settings [36, 38, 39] . In Germany, there is still a multicenter observational study ongoing in which approximately 30 patients have been included so far. An international multicenter randomized controlled trial is on its way next year in ARDS patients, comparing a conventional treatment strategy according to the NIH low tidal volume protocol with a strategy in which spontaneous arteriovenous carbon dioxide removal using the interventional lung assist device (Novalung, Hirrlingen) is applied, potentially allowing even further reduction of ventilator settings while keeping PaCO 2 and pH constant. The constancy of PaCO 2 and pH during the application of an arteriovenous carbon dioxide removal device allows even further reduction of plateau pressures at well-adjusted PEEP levels, thus reducing DP. It might even allow the patient to be kept breathing spontaneously on a high CPAP level from the very beginning, ideally while using a noninvasive interface. Very recent research further strongly supports the concept of preserving at least spontaneous breathing attempts to avoid diaphragmatic dysfunction. Unsupported spontaneous breaths during airway pressure release ventilation might be beneficial in recruiting especially basal parts of the lungs compared with controlled mechanical ventilation [40 •• ,41 ].
An arteriovenous carbon dioxide removal device can be established quickly, the device is simple, and monitoring is easy. However, an arterial cannulation is required, which excludes patients with serious peripheral arterial disease and has at least the potential risk to induce ischemia or an even nonperfused extremity. Additionally, the only driving force of the system is the heart of the patient. Twenty to twenty-five percent of the cardiac output pass as left to right shunt the device, thus excluding patients with cardiac insufficiency. The flow over the device is mostly determined by the mean arterial pressure, which can be influenced by vasopressor therapy; however, there is no possibility of directly influencing the flow per time. Table 1 summarizes potential advantages and disadvantages of spontaneous arteriovenous removal devices.
The future potential to integrate at any time an inline pump in an extracorporeal system supporting either an arteriovenous set-up or driving a veno-venous or venoarterial device would offer the chance to adapt the devices to the individual needs of a patient and would allow changing the vessels for blood outlet and inlet during the course. The realization of such a concept would certainly be another landmark for extracorporeal lung support procedures.
Conclusion
Extracorporeal membrane oxygenation is a potentially lifesaving therapeutic intervention in patients of all ages. It is a final option in patients with life-threatening hypoxemia, in whom all other treatment options have failed. However, with improved technology and experience and, in consequence, a low complication rate, the future potential of graduated extracorporeal support while using new technologies, especially in combination with application of lung protective ventilation strategies, might make clinicians rethink the role of extracorporeal lung support procedures in the treatment algorithm of ARDS.
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